Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017
, Cheng Liu1
, Meng-Na Wu, Teng Zhao, Guo-Lin Wang, Yang Yang, Hong-Jing Gu, Peng-Wei Cui, Yuan-Yuan Pang, Ya-Yun Tan, Hui Hang, Bao Lin, Jiang-Chun Qin, Li-Qun Fang
, Wu-Chun Cao
, and Li-Ling Cheng
Author affiliations: Beijing Institute of Microbiology and Epidemiology, Beijing, China (M.-J. Ma, M.-N. Wu, T. Zhao, G.-L. Wang, H.-J. Gu, L.-Q. Fang, W.-C. Cao); University of Florida, Gainesville, Florida, USA (Y. Yang); Suzhou Municipal Center for Disease Control and Prevention, Suzhou, China (C. Liu, P.-W. Cui, Y.-Y. Pang, Y.-Y. Tan, H. Hang, B. Lin, J.-C. Qin, L.-L. Chen)
Figure 2. GMTs (left) and individual titers (right) of antibodies to influenza A(H7N9) virus in serum samples collected from survivors, China, 2017: A) HI, B) NI, C) MN, D) IgG, and E) IgA. Red dashed line indicates threshold for seroprotective titer (HI, NI, and MN = 1:40) or limited detection titer (IgG = 1:400; IgA = 1:50). Error bars indicate 95% CIs. GMT, geometric mean titer; HI, hemagglutination inhibition; MN, microneutralization; NI, neuraminidase inhibition; P, patient.
Page created: June 22, 2018
Page updated: June 22, 2018
Page reviewed: June 22, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.